Last $643.21 MXN
Change Today 0.00 / 0.00%
Volume 0.0
ABT* On Other Exchanges
New York
SIX Swiss Ex
Sao Paulo
As of 4:09 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

abbott laboratories (ABT*) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/5/15 - $672.40
52 Week Low
01/28/14 - $483.20
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ABBOTT LABORATORIES (ABT*)

abbott laboratories (ABT*) Details

Abbott Laboratories manufactures and sells health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome, intrahepatic cholestasis or depressive symptoms, gynecological disorders, dyslipidemia, hypertension, hypothyroidism, pain, fever, and inflammation; and regulates physiological rhythm of the colon, as well as provides hormone replacement therapy and anti-infective and influenza vaccines. The company’s Diagnostic Products segment provides diagnostic systems and tests, such as immunoassay and clinical chemistry systems; assays for screening and diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, and physiological and infectious diseases; hematology systems and reagents; genomic-based tests; informatics and automation solutions; and diagnostic systems and tests for blood analysis, as well as instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents. Its Nutritional Products segment offers pediatric and adult nutritional products, such as various forms of prepared infant and follow-on formula. The company’s Vascular Products segment provides coronary, endovascular, vessel closure, and structural heart devices for the treatment of vascular diseases. Abbott Laboratories also offers blood glucose and glucose monitoring systems, test strips, and data management software and accessories for people with diabetes; and medical devices for the eye, such as cataract surgery, LASIK surgery, and contact lens care and dry eye products. The company primarily serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices, and government agencies. It has strategic alliance with Fonterra Co-operative Group Ltd. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

69,000 Employees
Last Reported Date: 02/21/14
Founded in 1888

abbott laboratories (ABT*) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.9M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $969.7K
Executive Vice President, General Counsel and...
Total Annual Compensation: $650.0K
Executive Vice President of Diagnostic Produc...
Total Annual Compensation: $614.6K
Executive Vice President of Corporate Develop...
Total Annual Compensation: $629.5K
Compensation as of Fiscal Year 2013.

abbott laboratories (ABT*) Key Developments

Abbott Laboratories Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

Abbott Laboratories Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Abbott Laboratories Announces Early Results of Cash Tender Offer by its Chilean Subsidiary

Abbott Laboratories said early results for a cash tender offer by its Chilean subsidiary for its outstanding 5.125% Senior Notes due 2022 showed an aggregate of $292.9 million principal amount representing 97.6% of outstanding notes were tendered. The company said it accepted for payment all notes that were validly tendered and not subsequently withdrawn. The tender offer will expire at 12 p.m. Eastern U.S. time on Jan. 14, 2015, unless extended or earlier terminated.

AB-Biotics Agrees Distribution Deal with Abbott for I3.1 Probiotic in Spain

AB-Biotics has finalised a commercial agreement with Abbott Pharmaceuticals (US) to distribute, promote, and market I3.1 probiotic (a strain that targets bloating, gas formation, and pain). Abbott will handle the exclusive promotion of the I3.1 probiotic in Spain, while the Spanish biotechnology firm focuses on R&D and commercialising its personalised medical product pipeline. AB-Biotics has been expanding its system of granting licensing agreements with other companies since 2012. However, the tie-up with Abbott Pharmaceuticals marks the first licensing agreement for I3.1 probiotic in Europe.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABT*:MM $643.21 MXN 0.00

ABT* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,744 GBp +18.50
Danaher Corp $83.79 USD -0.85
Eli Lilly & Co $71.94 USD +0.21
Medtronic PLC $74.55 USD -0.71
Teva Pharmaceutical Industries Ltd $58.41 USD -0.65
View Industry Companies

Industry Analysis


Industry Average

Valuation ABT* Industry Range
Price/Earnings 34.3x
Price/Sales 3.0x
Price/Book 2.9x
Price/Cash Flow 24.3x
TEV/Sales 2.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBOTT LABORATORIES, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at